Abstract:Importance: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS. Observations: In 2016, the updated guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Since these recommendations were published, new randomized clinical trials have studied different regimens and durations of antiplatelet therapy. Recommendations vary according to the risk of bleeding. If bleeding risk is low, prolonged DAPT may be considered, although the optimal duration of prolonged DAPT beyond 1 year is not well established. If bleeding risk is high, shorter duration (ie, 3-6 months) of DAPT may be reasonable. A high risk of bleeding traditionally is defined as a 1-year risk of serious bleeding (either fatal or associated with a ≥3-g/dL drop in hemoglobin) of at least 4% or a risk of an intracranial hemorrhage of at least 1%. Patients at higher risk are 65 years old or older; have low body weight (BMI <18.5), diabetes, or prior bleeding; or take oral anticoagulants. The newest P2Y12 inhibitors, prasugrel and ticagrelor, are more potent, with high on-treatment residual platelet reactivity of about 3% vs 30% to 40% with clopidogrel and act within 30 minutes compared with 2 hours for clopidogrel. Clinicians should avoid prescribing prasugrel to patients with a history of stroke or transient ischemic attack because of an increased risk of cerebrovascular events (6.5% vs 1.2% with clopidogrel, P = .002) and should avoid prescribing it to patients older than 75 years or who weigh less than 60 kg. The ISAR-REACT-5 trial found that prasugrel reduced rates of death, myocardial infarction, or stroke at 1 year compared with ticagrelor among patients with ACS undergoing percutaneous coronary intervention (9.3% vs 6.9%, P = .006) with no significant difference in bleeding. Recent trials suggested that discontinuing aspirin rather than the P2Y12 inhibitor may be associated with better outcomes. Conclusions and relevance: Dual antiplatelet therapy reduces rates of cardiovascular events in patients with acute coronary syndrome. Specific combinations and duration of dual antiplatelet therapy should be based on patient characteristics-risk of bleeding myocardial ischemia.

Application of Clopidogrel in the Treatment of Coronary Artery Disease

The Application of Triple Antithrombotic Therapy Combined with Aspirin,Clopidogrel and Warfarin in Patients with Coronary Heart Disease

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Advances of Antiplatelet Therapies

Analysis of clinical application of ticagrelor, a new oral antiplatelet drug

Current status and progress of percutaneous coronary intervention-related platelet P2Y12 receptor blockers

Progress of Research on Clopidogrel Resistance in the Patients with Acute Coronary Syndrome

Consideration and Implication of Clopidogrel Resistance in Era of Percutaneous Coronary Intervention: core recognition and benefit improvement

Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications

Balancing benefits and risks of oral antiplatelet strategies in patients with coronary artery diseases: an evolving issue.

Facts and controversies of aspirin and clopidogrel therapy

Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome

Research progress of antiplatelet drug "nonresponder"

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed

Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review

De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review

Current situation of platelet function tests and their clinical application status during antiplatelet treatment

Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review

Clinical study on dual antiplatelet therapy with ciopidogrel and aspirin in patients with ST-segment elevation acute myocardial infarction: a systematic review

Clinical pharmacology of antiplatelet drugs